Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit